Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400148 | 0.93 | POLRMT (0.39) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL25400176 | 0.87 | POLRMT (0.33) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL16708506 | 0.87 | POLRMT (0.51) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL16708516 | 0.80 | POLRMT (0.42) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL25402822 | 0.80 | POLRMT (0.51) | POLRMT | |
| SCHEMBL16708532 | 0.77 | POLRMT (0.40) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL16708517 | 0.77 | POLRMT (0.40) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL16710712 | 0.77 | TMPRSS2 (0.39) | POLRMTTMPRSS2NPC1ALDH1A1ATM | |
| SCHEMBL25399504 | 0.76 | TMPRSS2 (0.44) | TMPRSS2NPC1ALDH1A1ATMTDP1 | |
| SCHEMBL19101806 | 0.74 | TMPRSS2 (0.42) | TMPRSS2NPC1ALDH1A1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLRMT 2/4885TMPRSS2 2730/4885NPC1 1180/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLRMT 2/4885TMPRSS2 2730/4885NPC1 1180/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | POLRMT 2/4885TMPRSS2 2730/4885NPC1 1180/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | POLRMT 2/4885TMPRSS2 2730/4885NPC1 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.